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ABSTRACT
Solid dispersions (SDx) containing Indomethacin (IND), a poorly water-soluble drug, and the disintegrant
excipient sodium croscarmellose (SC) were prepared by a co-drying method and characterized by Infrared
spectroscopy (FT-IR), X-ray diffraction (XRD), differential scanning calorimetry (DSC) and scanning electron
microscopy (SEM). An FT-IR analysis performed on IND-SC solid dispersion and their physical mixtures
indicated that IND does not interact with SC in the solid state. An analysis of the information produced by
DSC, XRD, and SEM confirmed that the crystalline α-form of IND was homogeneously incorporated into
SDx. IND release from SDx was significantly greater than that from its corresponding physical mixtures with
the high homogeneous molecular dispersion and the crystalline modification of IND appearing to be the
cause. This behavior may have a beneficial effect on the biopharmaceutical performance of this drug.  
KEY WORDS: Solid dispersions, croscarmellose sodium, indomethacin, dissolution rate, solid state characterization,
co-processed material
INTRODUCTION
The bioavailability of poorly water-soluble
drugs that undergo dissolution rate-limited
gastrointestinal absorption can generally be
improved by innovative formulation strategies
such as the preparation of solid dispersions (1).
The resulting increase in the dissolution rate is
especially useful for Class II compounds
(Biopharmaceutical Classification System, BCS),
which have low gastrointestinal solubility and
high permeability (2).
Solids dispersions (SDx), defined as molecular
mixtures of poorly water-soluble drugs and
hydrophilic carriers, have been proposed as an
alternative for the improvement of the
dissolution rate of this class of drugs. These
systems can be prepared by fusion, dissolution
or a combination of fusion-dissolution (3).
Numerous reports about solid dispersions
comprising a great variety of carriers,
drug/carrier ratios and methods of preparation
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have already been published (4), with
explanations for the probable mechanism of
dissolution enhancement (5, 6). 
According to the BCS, Indomethacin (IND) is
a class II compound, a hydrophobic and poorly
water soluble antirheumatic agent used in many
pharmaceutical preparations (7, 8). Different
polymorphic forms of IND exist (9). Several
methods for increasing the dissolution rate of
IND have been investigated, such as  increase
of wettability (incorporation of a surfactant)
(10, 11), the use of a higher energy crystalline
form (appropriate selection of the polymorph)
(12, 13) and the increase of the particle surface
exposed to the medium (14). An, as yet un-
explored strategy, is the incorporation of the
drug in an SDx based on a material that
facilitates water intake, granule disruption and
the spread of fine particles into the dissolution
medium. Among these types of materials,
disintegrating excipients are usually included in
the tablet composition in order to produce a
quick rupture of the compact, thus facilitating
exposure of a greater surface area available for
drug dissolution.
One of the most commonly used disintegrating
excipients is sodium croscarmellose (SC), which
is a crosslinked polymer of sodium carboxy-
methylcellulose used in oral pharmaceutical for-
mulations as a disintegrant in capsules, tablets
and granules, in concentrations from about
0.5% to 25% (15).
The objective of this study was to develop a
process aimed at preparing binary solid
dispersions using croscarmellose sodium as the
carrier. This study also includes the physico-
chemical characterization of SDx and an in vitro
evaluation of the influence of this material on
the IND dissolution rate.
MATERIALS AND METHODS
Materials
The following substances were used for the
solid dispersion preparations:  γ or I form of
IND (Pharmaceutical grade, Parafarm, Buenos
Aires, Argentina) and SC (AcDiSol®, FMC
Biopolymer, Montevideo, Uruguay). Other
chemicals used in this study were of analytical
grade. All the materials were used as received.
Methods
Preparation of solid dispersions by the solvent
evaporation method
Solid dispersions with different concentrations
of IND and SC (SDx, Table 1) were prepared as
follows: different amounts of SC were
suspended in 50 ml of ethanol and different
amounts of IND were dissolved in 100 ml of
ethanol. Then, the suspension and the solution
were thoroughly mixed. The solvent was
evaporated under reduced pressure using a
rotary evaporator at 60EC and the resulting
solid materials were stored in  closed screw-cap
vials at 8EC until used.
Preparation of physical mixtures
Physical mixtures containing different
concentrations of the drug and SC (PMx in
Table 1) were prepared by mixing IND with the
carrier in a mortar until homogenous mixtures
were obtained by visual examination. The
powders were stored in  screw-cap vials at 
(8EC) until used.












SD1 PM1 5 95
SD2 PM2 10 90
SD3 PM3 25 75
SD4 PM4 50 50
Solid product characterization
Fourier-transform infrared spectroscopy (FT-IR)
KBr disks containing the solid dispersions or
the physical mixtures in a concentration of 1%
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were evaluated using a Nicolet 5SXC FT-IR
Spectrometer (Thermo Scientific, USA).
Powder X-ray Diffraction (PXRD)
The XRD patterns were recorded using a
Rigaku Miniflex 2000 diffractomer (Rigaku,
Japan) (Δ: 1.5418 Å using a Bragg-Brentano
geometry) and the radiation was generated by a
Cu Kα lamp. The instrument was operated in
the continuous scan mode with a scanning
speed of 2°/min. The scan range was 5-70°,
2θ/θ, with a scan speed of 0.066°, 2θ/s.
Differential scanning calorimetry (DSC)
A differential scanning calorimeter (Modulated-
DSC 2920 model, TA-instruments, USA) was
used under a nitrogen gas flow of 60 ml/min. at
a heating rate of 20°C/min from 25 to 250°C.
The samples with weights of ~1 to 2 mg were
sealed in open aluminum pans. The
temperature was calibrated using pure indium
with a melting point of 156.60°C. Results were
expressed as maximum temperature (EC) and
ΔH (J/g). Melting enthalpy values of the drug
in each binary mixture or SDx, in particular, are
reported as functions of the IND proportion in
the sample. 
Scanning Electron Microscopy (SEM)
The samples were coated with gold in a
PELCO 91000 sputter coater (Ted Pella,
Canada). Particle morphology was assessed in
an EVO 40-XVP, LEO Scanning Electron
Microscope (LEO, United Kingdom).
Dissolution experiment
A dissolution test was performed using a
SOTAX AT 7 Smart (USP30 dissolution
apparatus 2) (Sotax, Switzerland) with the
rotational paddle speed kept constant at 100
rpm and water bath equilibrated to 37.0 ±
0.5EC. The amount of the sample material used
was equivalent to 75 mg of the drug. 
The dissolution medium was 1 volume of pH
7.2 phosphate buffer mixed with 4 volumes of
water to a total amount of 750 ml. 5 ml aliquots
were withdrawn at predetermined intervals over
a period of 2 hours. The same amount of fresh
medium was used to keep the volume constant
throughout the test. The samples were filtered
and IND was assayed at 320 nm using a UV-
Vis spectrophotometer (Termo Evolution 300,
Thermo Scientific, USA). Three replicates of
each dissolution test were assayed. The
Similarity Factor f2 was calculated for
comparison with  in vitro dissolution of solid
dispersions of drug alone and in physical
mixtures. A model-independent mathematical
approach proposed by Moore and Flanner (16)
for calculating a Similarity Factor (f2) was used
to compare the dissolution profiles of different
samples. The f2 value was calculated using
Equation 1.
 




























50log 1+ 1n R
.
Where, 
Rt and Tt represent the cumulative percent
dissolved for the reference (physical mixture)
and the test (solid dispersion) samples at each
time point to be compared and “n” is the
number of dissolution time points. An f2 value
between 50 and 100 suggests similarity between
the two release profiles, whereas an f2 value
below 50 suggests dissimilarity between the
release profiles.
RESULTS AND DISCUSSION
Indomethacin can arrange its crystalline
structure into four different polymorphic
forms, (17,18) although the α and γ-forms are
the most reported (9). The α-form is kinetically
stable (metastable), whereas the γ-form is
thermodynamically stable (stable). At room
temperature, both forms grow concomitantly
from ethanol solutions in glass containers (19).
 
The γ-form has a melting temperature (Tm) of
161°C, whereas the α- form has a Tm of 155°C
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Figure 2 XRD patterns of SD4, their precursors and the
physical mixture.
Figure 1 The FT-IR spectra of SD4, PM4 and IND.
and a greater rate of dissolution (intrinsic
solubility of a given molecule in a given solvent
is constant regardless of the thermodynamic
state of its crystalline solid form as well as
particle size) than the γ-form. In the γ-form, the
dominating feature is the crystal packing within
the hydrogen bonding of carboxylic acid
groups, in order to form molecular dimers. In
contrast, in the α-form, the asymmetric unit
consists of three molecules with the third
hydrogen molecule bonded to the molecular
dimer being formed by the remaining two
molecules (20).
To detect any possible IND crystalline changes
in the SDx samples due to its processing, the
FT-IR, DSC and the X-ray powder diffraction
data of SD1 and SD4 were  compared with PM1
and PM4. In the FT-IR, the 1700 cm
-1 region of
the each spectrum was analyzed (21). Figure 1
shows examples of the IND, SD4 and PM4
peaks. The signals appearing at 1717 and 1692
cm-1 in the IND and PM4 spectra may be
attributed to the asymmetric stretching of
carboxylic acid in the dimer structure. This
arrangement is characteristic for the γ-form,
because of the presence of the anhydride
groups formed as a consequence of the
interaction of the acidic hydrogen with the
amide-carbonyl group of a second molecule of
IND (20).
 
The SD4 spectrum presented a peak at
1730 cm-1, suggesting that the carbonyl group
of COOH was involved in a different type of
hydrogen bond in the crystal lattice, which
might be attributed to a change in the
polymorphic form of IND. Andronis and
Zografi (22) found that the maximun
nucleation rate for α-indomethacin occurred at
60°C, corresponding to the temperature utilized
for the SDx preparation. It is therefore probable
that IND was present as the α-form in the SDx.
No other changes in the FT-IR pattern were
identified between SDx and PMx indicating that
the drug did not interact with the polymer in
the SDx. 
The X-Ray diffraction patterns of these
substances were also determined as shown in
Figure 2. The IND diffractogram revealed the
characteristic crystalline pattern of the γ-form,
whereas, for SC, a pattern corresponding to an
amorphous solid was observed. In the case of
phys ica l  mixtures ,  a  super imposed
diffractrogram reflecting the additive behavior
of both components could be observed.
Regarding SDx, the crystalline diffraction
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Figure 3 Comparative SEM photographs of IND: (a)
2000x and (b) 6000x, SC: (c) 2000x and (d) 6000x, SD4: 
(e) 2000x and (f) 6000x, PM4: (g) 2000x and (h) 6000x.
Figure 4 Dissolution profile of IND, solid dispersions and physical mixtures of IND and SC in buffer pH 7.2
solution.
pattern corresponding to IND was quite
different, with, the signal observed at 8.6°, 2θ
corresponding to the α-form of IND and
suggesting that the crystalline arrangement of
IND changed as a consequence of its inclusion
in SDx (23).
The thermal events associated to probable
phase transitions were also studied. The DSC
curve of γ-IND exhibited a sharp endothermic
peak at 160.5 EC (ΔH 120 J/g), which
corresponded to its melting point. The
temperature at which this transition occurred
also remained unchanged for PM1 (160.5EC,
ΔH 97 J/g) and PM4 (161.0ΔC, ΔH 128 J/g).
The melting enthalpy of γ-IND measured in
PM1 was lower than that of the pure drug. This
result could be attributed non-homogeneity
associated with the low proportion of the drug
in this particular blend. On the other hand, the
solid dispersions SD1 and SD4 showed
endothermic peaks at 155.1EC (ΔH 107 J/g)
and 155.2EC (ΔH 109 J/g), respectively,
corresponding to the fusion of the α-IND
crystals. The measured enthalpy values for SDx
are in conformity with previously published
data (24).
Figure 3 shows SEM photographs of SD4, PM4
and their precursors. The pure drug image of
SEM showed crystalline particles of irregular
shape, while the SC pictures revealed the
fibrous nature of the excipient. In the physical
mixture, the SC existed as individual particles
with IND dispersed in its native crystalline
form. Comparatively, the morphology of the
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SD4 was quite different to the corresponding
physical mixture, the drug being present in the
latter as needles on the surface of the SC
particle, thereby losing the original size and
shape of the IND (21).
In order to evaluate the drug dissolution
kinetics of IND from SDx, these results were
compared with those of the corresponding
physical mixture and IND alone. As shown in
Figure 4 and Tables 2 and 3, SDx and PMx
exhibited faster dissolution rates than IND
alone in all cases. This may be mainly attributed
to the improvement of wetting properties of
the drug mixed or co-processed with the
hydrophilic carrier, as the high swelling and
hydration capacity of SC increases the water
uptake of the powder (25).
The incorporation of IND as a solid dispersion
seems to be important for a very fast
dissolution at an early stage of the process,
since a greater burst effect of SDx was not
observed in the case of PMx. In addition, the
change in the crystalline arrangement of IND
could  also have  an  additional  effect on the 
On the other hand, similar dissolution rates
(f2>50) were observed for different SDx (SD1,
SD2, SD3 and SD4) as well as for different PMx
(PM1, PM2, PM3 and PM4). Although the
tendency for the dissolution rate to increase 
was related to the increase of SC in SDx, it was
noted than SD3 showed a faster dissolution rate
at the beginning of the process (<5 min),
whereas SD1 and SD2 (with higher SC
proportions) were less effective as dissolution
rate enhancers.  Although further studies are
necessary to explain this behavior, the diluting
effect of SC may be the reason why IND is less
exposed to the aqueous environment, thus
leading to a delay in the dissolution. This
hypothesis would infer that in the case of SD4,
the maximum increase in the dissolution rate
would be expected since, IND is present at the
highest proportion. 
However as shown in Figure 4, SD4 was not
able to release IND any faster than SD3. Based
on this fact, it is suggested that the amount of
SC was not enough to the able to produce a
noticeable dissolution  effect and consequently
an increase in the drug dissolution rate.
Table 2 Percentage of Indomethacin dissolved in the dissolution medium.
% of IND dissolved
SDx 1 min 3 min 5 min 15 min PMx 1 min 3 min 5 min
1 70.8 60.5 62.3 63.5 1 32.4 53.2 59.8
2 64.4 64.1 62.9 60.7 2 36.7 51.7 60.7
3 75.2 73.3 78.8 74.4 3 18.7 43.9 53.9
4 41.0 53.7 63.0 77.3 4 17.8 44.8 53.8
IND 3.43 5.52 9.04 23.3 IND 3.43 5.52 9.04
Table 3 Similarity factor values of dissolution profiles.
SAMPLES CONTAINING
DIFFERENT % of IND
SIMILARITY FACTOr (f2)
SDx- PMx SDx- IND PMx- IND
5 41.63 20.78 16.96
10 40.83 21.20 18.19
25 39.97 15.28 20.11
50 55.28 18.37 18.86
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CONCLUSION
A new binary material of IND and a
disintegrant excipient (SC) was obtained by a
simple method. The SC favorably influenced in
vitro IND dissolution by means of two principal
effects: first, the process by which SDx was
obtained produced a γ6α transition, leading to
an IND polymorph that exhibited a greater rate
of dissolution and, second, the very efficient
water uptake properties of SC made the rapid
wetting of SDx possible, thus facilitating the
drug dissolution. It was observed that this
effect was strongly related to the percentage of
SC present in SDx. Therefore, according to
these results, an improvement of IND
bioavailability when administered as SDx would
be expected. Nevertheless, further studies are
necessary in order to confirm this hypothesis,
including those that observe the effect of
dissolution rates when such PMxs and SDxs are
compressed into tablets.
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